Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SX-682 by Syntrix Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
SX-682 by Syntrix Pharmaceuticals for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
SX-682 by Syntrix Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval
SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
SX-682 by Syntrix Pharmaceuticals for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Recurrent Head And Neck Squamous Cell...
SX-682 by Syntrix Pharmaceuticals for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...